SCHEMBL5160589

SCHEMBL5160589

COC(=O)CC(=O)c1ccc[nH]1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
RAB9A P51151 8/20 0.50
NPC1 O15118 5/20 0.50
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HSD17B10 Q99714 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
THRB P10828 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160927 0.84 RAB9A (0.49) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL5162812 0.83 TSHR (0.47) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL5162856 0.83 RAB9A (0.57) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL9383990 0.82 TSHR (0.54) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL9664550 0.81 TSHR (0.56) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL14803836 0.79 RAB9A (0.59) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL13041458 0.78 TSHR (0.53) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL5162800 0.78 TSHR (0.53) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL5158635 0.77 TSHR (0.56) TSHRRAB9ANPC1GAASMN1; SMN2
SCHEMBL7644636 0.77 TSHR (0.47) TSHRRAB9ANPC1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO TSHR 4474/4885RAB9A 3428/4885NPC1 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.